Praxis Precision Medicines Inc. announced on July 17, 2025, that the U.S. Food and Drug Administration has granted breakthrough therapy designation (BTD) for their drug relutrigine. This designation is specifically for pediatric use in treating patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The BTD facilitates expedited development and review processes for drugs that aim to treat serious conditions, where preliminary clinical evidence suggests substantial improvement over existing therapies. The designation was supported by positive results from the Phase 2 EMBOLD study and 11-month data from its open-label extension. Additionally, Praxis has commenced the EMERALD study to further evaluate relutrigine across all DEEs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.